Lubiprostone + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Irritable Bowel Syndrome

Conditions

Irritable Bowel Syndrome, Constipation

Trial Timeline

May 1, 2005 → Jul 1, 2006

NCT ID

NCT00399542

About Lubiprostone + Placebo

Lubiprostone + Placebo is a phase 3 stage product being developed by Mallinckrodt Pharmaceuticals for Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00399542. Target conditions include Irritable Bowel Syndrome, Constipation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03097861	Phase 3	Completed	Mar 13, 2017	Aug 17, 2017	Chronic Idiopathic Constipation
NCT01298219	Phase 3	Completed	Dec 1, 2010	Nov 1, 2011	Opioid-induced Bowel Dysfunction
NCT00595946	Phase 3	Completed	Aug 1, 2007	Mar 1, 2009	Opioid-Induced Bowel Dysfunction
NCT00597428	Phase 3	Completed	Aug 1, 2007	Mar 1, 2009	Opioid-Induced Bowel Dysfunction
NCT00399542	Phase 3	Completed	May 1, 2005	Jul 1, 2006	Irritable Bowel Syndrome

Competing Products

20 competing products in Irritable Bowel Syndrome

See all competitors

Product	Company	Stage	Hype Score
linaclotide + placebo	Astellas Pharma	Phase 2	52
YM060 + Placebo	Astellas Pharma	Phase 3	77
Ramosetron + Placebo	Astellas Pharma	Approved	85
Ramosetron + Placebo	Astellas Pharma	Approved	85
YM060	Astellas Pharma	Phase 3	77
YM060 + placebo	Astellas Pharma	Phase 2	52
YM060	Astellas Pharma	Phase 3	77
linaclotide + Placebo	Astellas Pharma	Phase 3	77
Ramosetron	Astellas Pharma	Pre-clinical	23
YM060	Astellas Pharma	Phase 2	52
ONO-2952 + Placebo comparator	Ono Pharmaceutical	Phase 2	52
ONO-2952 + ONO-2952 Matching Placebo	Ono Pharmaceutical	Phase 2	52
duloxetine	Eli Lilly	Approved	85
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)	AbbVie	Phase 3	77
25mg Eluxadoline + 100mg Eluxadoline	AbbVie	Phase 3	77
Eluxadoline + Placebo	AbbVie	Phase 2	52
Placebo + Linaclotide	AstraZeneca	Phase 3	77
Tegaserod	Novartis	Pre-clinical	23
DNK333	Novartis	Phase 2	52
SMS995 + Placebo	Novartis	Phase 1	33

Other Products from Mallinckrodt Pharmaceuticals

Lubiprostone + Lubiprostone + LubiprostoneApproved

Lubiprostone + PlaceboPhase 3